Pasar al contenido principal

DIVISION ASIMETRICA Y COMPETICION CELULAR EN EL DESARROLLO Y TUMOROGENESIS DEL SISTEMA NERVIOSO

PID2021-123196NB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Latest News from the "Guardian": p53 Directly Activates Asymmetric Stem Cell Division Regulators

  • Carmena, Ana
Since its discovery in 1979, the human tumor suppressor gene TP53-also known as the "guardian of the genome"-has been the subject of intense research. Mutated in most human cancers, TP53 has traditionally been considered a key fighter against stress factors by trans-activating a network of target genes that promote cell cycle arrest, DNA repair, or apoptosis. Intriguingly, over the past years, novel non-canonical functions of p53 in unstressed cells have also emerged, including the mode of stem cell division regulation. However, the mechanisms by which p53 modulates these novel functions remain incompletely understood. In a recent work, we found that Drosophila p53 controls asymmetric stem cell division (ASCD) in neural stem cells by transcriptionally activating core ASCD regulators, such as the conserved cell-fate determinants Numb and Brat (NUMB and TRIM3/TRIM2/TRIM32 in humans, respectively). In this short communication, we comment on this new finding, the mild phenotypes associated with Drosophila p53 mutants in this context, as well as novel avenues for future research., Our lab work on p53 was funded by Spanish Grants from the Ministry of Economy and Competitiveness (BFU2015-64251); the Ministry of Science, Innovation, and Universities (PGC2018-097093-B-100); the Ministry of Science and Innovation (PID2021-123196NB-100); the Generalitat Valenciana Prometeo/2021/052 grant; and the FEDER (European Regional Development Fund)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Human RAP2A homolog of the Drosophila asymmetric cell division regulator Rap2l targets the stemness of glioblastoma stem cells

  • Franco, Maribel
  • Gargini, Ricardo
  • Barberá, Víctor Manuel
  • Saceda, Miguel
  • Carmena, Ana
Asymmetric cell division (ACD) is a fundamental process to balance cell proliferation and differentiation during development and in the adult. Cancer stem cells (CSCs), a very small but highly malignant population within many human tumors, are able to provide differentiated progeny by ACD that contribute to the intratumoral heterogeneity, as well as to proliferate without control by symmetric, self-renewing divisions. Thus, ACD dysregulation in CSCs could trigger cancer progression. Here, we consistently find low expression levels of RAP2A, the human homolog of the Drosophila ACD regulator Rap2l, in glioblastoma (GBM) patient samples, and observe that scarce levels of RAP2A are associated with poor clinical prognosis in GBM. Additionally, we show that restitution of RAP2A in GBM neurosphere cultures increases the ACD of glioblastoma stem cells (GSCs), decreasing their proliferation and expression of stem cell markers. Our results support that ACD failures in GSCs increase their spread and ACD amendment could contribute to reduce the expansion of GBM., We thank the Bloomington Drosophila Stock Center at the University of Indiana and the Developmental Studies Hybridoma Bank at the University of Iowa for kindly providing fly strains and reagents. RG was funded by ‘P through the project Miguel Servet Contracts’ (CP21/00116), PI22/01171, and co-funded by the European Union. MS was supported by the Spanish grant from the Instituto de Salud Carlos III (ISCIII) PI22/00824. AC was financed by the Spanish grants from the Ministry of Science, Innovation and Universities (PGC2018-097093-B-100), the Ministry of Science and Innovation (PID2021-123196NB-100), the Generalitat Valenciana Prometeo/2021/052 grant, and the European Regional Development Fund (FEDER). The ‘Instituto de Neurociencias’ in Alicante is a ‘Severo Ochoa Center of Excellence in R&D’. Our group belongs to ‘Conexión Cáncer (CSIC)’., Peer reviewed